Live Breaking News & Updates on Ndia And Vancouver

MUMBAI, India and VANCOUVER, BC, July 13, 2022 /PRNewswire/ Glenmark Pharmaceuticals Limited (Glenmark), an innovation-driven, global pharmaceutical company and SaNOtize Research and Development Corp, today announced that The Lancet Regional Health Southeast Asia (TLRHSEA) - peer reviewed, high impact journal published the successful phase 3 clinical trial results of SaNOtize's Nitric Oxide Nasal Spray (NONS) study titled: 'SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: A randomized trial'. https://www.thelancet.com/journals/lansea/article/PIIS2772-3682(22)00046-4/fulltext "We are excited to publish the study of the novel Nitric Oxide Nasal Spray, which positively impacts the lives of people, in The Lancet group of journals. The robust double-blind trial demonstrated significant efficacy and remarkable safety of NONS. This therapy has the potential to make a crucial contribution to COVID-19 management, with its ease of use in ....

Hong Kong , British Columbia , East Timor , Republic Of , Sri Lanka , Monika Tandon , Gilly Regev , Sanotize Co , Lancet Regional Health Southeast Asia , Strategic Partnership , Glenmark Pharmaceuticals Limited , Sanotize Research , Glenmark Pharmaceuticals Ltd , Development Corp , Clinical Development , Nitric Oxide Nasal Spray , Glenmark Pharmaceuticals , Progression Scale Score , Ndia And Vancouver , July 13 , 022 Prnewswire Glenmark Pharmaceuticals Limited , N Innovation Driven , Lobal Pharmaceutical Company And Sanotize Research Development Corp , Oday Announced That The Lancet Regional Health Southeast Asia Tlrhsea Peer Reviewed , Igh Impact Journal Published The Successful Phase 3 Clinical Trial Results Of Sanotize 39s Nitric Oxide Nasal Spray Nons Study Titled 39 Sars Cov 2 Accelerated Clearance Usinga Novel Treatmenta Randomized Https Www Thelancet Com Journals Lansea Article Piis2772 3682 22 00046 4 Fulltext Quot We Are Excited To Publish , Hich Positively Impacts The Lives Of People ,